BlackRock, Inc. Amends Schedule 13G/A for Neogenomics Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Neogenomics Inc., reporting ownership of 18,861,974 shares, representing 14.6% of the common stock. The filing indicates a decrease of 562,614 shares (-2.8964%) compared to the previous report, with the value of the holdings increasing by $47,569,100.70 (33.5008%). The filing also notes that iShares Core S&P Small-Cap ETF holds more than five percent of the total outstanding common stock. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.